For reference: semaglutide · STEP 2.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
Can someone derive this rather than assert it?
Read STEP 2 by arm, because the arm is the unit of randomisation and every figure worth quoting is defined at that level. A programme that randomised several dose levels reports each one separately, with its own sample size and its own interval, and the pooled number that circulates afterwards describes a group nobody was assigned to. Take the primary publication and its supplementary tables rather than a summary of them: one is organised by arm, the other by whichever figure was largest. And check the estimand — what happened to everyone assigned, or what happens to those who kept taking it — because the two answer different questions and are routinely quoted as though they were one.
The honest answer is that appetite suppression is centrally mediated and gastric emptying is peripheral, and the two contribute different amounts in different people.
Gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
On the detail: central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.
The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.
Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.
edited 27 Apr 2026 by Dr_Priya_Raghunathan — corrected a unit error in the worked example
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.
Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.
It helps to be literal here: glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.
Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.
The half-life problem and the albumin-binding solution are the whole story of the class chemically.
Put another way, the endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.
Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.
Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.
Mechanism is a good guide to what to expect and a poor guide to how much.
The receptor is also expressed in the heart, kidney and vasculature, which is the plausible route for effects that are not obviously metabolic.
Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.
Glucose-dependence is the property to remember; it explains the safety profile on its own.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.